A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.

被引：0
|
作者：
Di Giacomo, Anna Maria
Annesi, Diego
Ascierto, Paolo Antonio
Calabro, Luana
Chiarion-Sileni, Vanna
Danielli, Riccardo
Del Vecchio, Michele
Ferraresi, Virginia
Ferrucci, Pier Francesco
Fonsatti, Ester
Guida, Michele
Giannarelli, Diana
Guidoboni, Massimo
Mandala, Mario
Quaglino, Pietro
Queirolo, Paola
Maccalli, Cristina
Parmiani, Giorgio
Maio, Michele
机构：
[1] Univ Hosp Siena, Med Oncol & Immunotherapy, Siena, Italy
[2] Univ Hosp Siena, Siena, Italy
[3] Ist Nazl Tumori IRCCS, Naples, Italy
[4] Veneto Oncol Inst, Padua, Italy
[5] Azienda Osped Senese, Siena, Italy
[6] Ist Nazl Tumori, I-20133 Milan, Italy
[7] Regina Elena Inst Canc Res, Rome, Italy
[8] European Inst Oncol, Milan, Italy
[9] Ist Oncol, Bari, BA, Italy
[10] IRCCS IRST, Immunotherapy & Somat Cell Therapy Lab, Meldola, Italy
[11] Papa Giovanni XIII Hosp, Bergamo, Italy
[12] Univ Turin, Dermatol Clin, Dept Med Sci, Turin, Italy
[13] Natl Inst Canc Res, Genoa, Italy
[14] Italian Network Tumor Biotherapy Lab, Siena, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9090
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma.
    Lowe, Michael C.
    Lesinski, Gregory B.
    Delman, Keith A.
    Yushak, Melinda Lynne
    Evans, Elizabeth E.
    Fisher, Terrence Lee
    Kudchadkar, Ragini Reiney
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.
    Reijers, Irene
    Rozeman, Elisa A.
    Menzies, Alexander M.
    Van de Wiel, Bart A.
    Eriksson, Hanna
    Suijkerbuijk, Karijn
    Van der Veldt, Astrid Aplonia Maria
    Kapiteijn, Ellen
    Hospers, Geke
    Klop, Willem M. C.
    Spillane, Andrew
    Scolyer, Richard A.
    Svane, Inge Marie
    Bastholt, Lars
    Schmidt, Henrik
    Larkin, James M. G.
    Van Akkooi, Alexander Christopher Jonathan
    Long, Georgina V.
    Blank, Christian U.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] TWO-YEAR OVERALL SURVIVAL (OS) RATES FROM A RANDOMIZED PHASE 2 TRIAL EVALUATING THE COMBINATION OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) VERSUS IPI IN PATIENTS WITH ADVANCED MELANOMA (MEL)
    Postow, Michael A.
    Chesney, Jason
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April
    Taylor, Matthew H.
    Ott, Patrick A.
    Jiang, Joel
    Horak, Christine
    Wolchok, Jedd D.
    Hodi, Stephen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 130 - 131
  • [44] A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study).
    Long, Georgina V.
    Atkinson, Victoria
    Menzies, Alexander M.
    Guminski, Alexander David
    Sandhu, Shahneen Kaur
    Brown, Michael Paul
    Liaw, Tracy
    Gonzalez, Maria
    Davison, Jill
    Paton, Elizabeth J.
    Scolyer, Richard A.
    Emmett, Louise
    McArthur, Grant A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.
    Tong, Thais M. L.
    Burgmans, Mark C.
    Van der Kooij, Monique
    Speetjens, Frank M.
    van Erkel, Arian R.
    van der Meer, Rutger W.
    van den Bosch, Shelley
    Jonker, Mare A.
    Roozen, Inge C. F. M.
    Lutjeboer, Jacob
    Rijksen, Fenna
    van Persijn-van Meerten, Els L.
    Martini, Chris H.
    Zoethout, Remco W. M.
    Tijl, Fred G. J.
    Blank, Christian U.
    Kapiteijn, Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Updated results from a phase 1/2 study of epacadostat (INCB024360) in combination with ipilimumab in patients with metastatic melanoma
    Gibney, G.
    Hamid, O.
    Lutzky, J.
    Olszanski, A.
    Gangadhar, T.
    Gajewski, T.
    Chmielowski, B.
    Hanks, B.
    Boasberg, P.
    Zhao, Y.
    Newton, R.
    Bowman, J.
    Maleski, J.
    Leopold, L.
    Weber, J. S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S106 - S107
  • [47] Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
    Postow, Michael
    Chesney, Jason
    Pavlick, Anna
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey
    Agarwala, Sanjiv
    Shaheen, Montaser
    Ernstoff, Marc
    Minor, David
    Salama, April
    Taylor, Matthew
    Ott, Patrick
    Jiang, Joel
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd
    Hodi, F. Stephen
    CANCER RESEARCH, 2016, 76
  • [48] CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
    Schenker, Michael
    Burotto, Mauricio
    Richardet, Martin
    Ciuleanu, Tudor
    Goncalves, Anthony
    Steeghs, Neeltje
    Schoffski, Patrick
    Ascierto, Paolo A.
    Maio, Michele
    Lugowska, Iwona
    Lupinacci, Lorena
    Leary, Alexandra
    Delord, Jean-Pierre
    Grasselli, Julieta
    Tan, David S.
    Friedmann, Jennifer E.
    Vuky, Jacqueline
    Tschaika, Marina
    Slepetis, Ruta
    Kollia, Georgia D.
    Pacius, Misena
    Huang, Ning
    Doshi, Parul
    Baden, Jonathan
    Di Nicola, Massimo
    CANCER RESEARCH, 2022, 82 (12)
  • [49] Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
    Hodi, F. Stephen
    Chesney, Jason
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth F.
    McDermott, David F.
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeff Rey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April K.
    Taylor, Matthew H.
    Ott, Patrick A.
    Horak, Christine
    Gagnier, Paul
    Jiang, Joel
    Wolchok, Jedd D.
    Postow, Michael A.
    LANCET ONCOLOGY, 2016, 17 (11): : 1558 - 1568
  • [50] Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
    Atkins, Michael B.
    Lee, Sandra J.
    Chmielowski, Bartosz
    Tarhini, Ahmad A.
    Cohen, Gary I.
    Truong, Thach-Giao
    Moon, Helen H.
    Davar, Diwakar
    O'Rourke, Mark
    Stephenson, Joseph J.
    Curti, Brendan D.
    Urba, Walter J.
    Brell, Joanna M.
    Funchain, Pauline
    Kendra, Kari L.
    Ikeguchi, Alexandra P.
    Jaslowski, Anthony
    Bane, Charles L.
    Taylor, Mark A.
    Bajaj, Madhuri
    Conry, Robert M.
    Ellis, Robert J.
    Logan, Theodore F.
    Laudi, Noel
    Sosman, Jeffrey A.
    Crockett, David G.
    Pecora, Andrew L.
    Okazaki, Ian J.
    Reganti, Sowjanya
    Chandra, Sunandana
    Guild, Samantha
    Chen, Helen X.
    Streicher, Howard Z.
    Wolchok, Jedd D.
    Ribas, Antoni
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 186 - +
12345